Fundraising Fox

Opus Genetics

NASDAQ: IRD

Raleigh, US · Founded 2021 · Delaware corporation · 46 employees on LinkedIn · 2 known investors

Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing therapies for inherited retinal diseases (IRDs) and other retinal and refractive disorders. It focuses on genetic medicine aimed at preserving and restoring vision for patients with rare eye conditions.

BiotechDeep TechDigital HealthHealthtechMedical Devices

Founders & leadership

BR
BENJAMIN R. YERXAExecutive
GMGeorge Magrath
George MagrathChief Executive Officer
BYBen Yerxa
Ben YerxaPresident
RGRobert Gagnon
Robert GagnonChief Financial Officer
JSJoe Schachle
Joe SchachleChief Operating Officer
AJAsh Jayagopal
Ash JayagopalChief Scientific and Development Officer
STSally Tucker
Sally TuckerChief Medical Officer
STSarah Tuller
Sarah TullerChief Regulatory Officer
CEChris Ernst
Chris ErnstChief Technology Officer
JBJEAN BENNETT
JEAN BENNETTNamed on SEC filing
RK
RUSSELL KELLEYNamed on SEC filing

Investors · 2

Michigan Capital NetworkGrand Rapids
Oberland CapitalNew York · $50M – $300M

Reported raises · per SEC filings

Form D private placements

$14M disclosed across 2 rounds · 2021–2023

▶$4.5MraisedJun 2023 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • JEAN BENNETTDirector
  • RUSSELL KELLEYDirector
  • BENJAMIN R. YERXAExecutive Officer, Director
  • ADRIENNE GRAVESDirector
Offering amount
$20M
Amount sold
$4.5M
First sale
Jun 2023
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$9.5MraisedAug 2021 · 5 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • BENJAMIN R. YERXAExecutive Officer, Director
  • JEAN BENNETTDirector
  • RUSSELL KELLEYExecutive Officer, Director
Offering amount
$19M
Amount sold
$9.5M
First sale
Aug 2021
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Ois20 shared keywordsOIS is a conference and community, active since 2009, focused on eye care and ophthalmology innovation, connecting startups, strategics, investors, and clinicians. It provides curated programming, networking, and access to new technologies in the ophthalmology industry.

Companies competing with Opus Genetics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Citizens reiterates Opus Genetics stock rating ahead of trial data By Investing.cominvesting.com · Aug 2026Opus Genetics (Nasdaq: IRD) posts Q2 2026 loss, extends cash runway into 2029stocktitan.net · Aug 2026Opus Genetics completes enrollment in LCA5 gene therapy trial By Investing.cominvesting.com · Aug 2026Opus Genetics Secures $155 Million Financing to Accelerate Gene Therapy Pipeline — Foundation Fighting Blindnessfightingblindness.org · Apr 2026

Frequently asked questions

What does Opus Genetics do?
Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing therapies for inherited retinal diseases (IRDs) and other retinal and refractive disorders. It focuses on genetic medicine aimed at preserving and restoring vision for patients with rare eye conditions.
Who are Opus Genetics's investors?
Opus Genetics's investors include Michigan Capital Network, Oberland Capital.
How much funding has Opus Genetics raised?
Opus Genetics has disclosed $14M raised across 2 rounds.
Where is Opus Genetics headquartered?
Opus Genetics is headquartered in Raleigh, US.